logo
Products
Services
Resources
Selection Guides
About
iFluor® 546 Anti-human CD71 Antibody
HI166
HI166 is an anti-human monoclonal antibody that is specific for the CD71 antigen. CD71 (sometimes called Transferrin receptor or TFRC) is a 95 kD member of the Transferrin receptor family that is located on the surface of cells such as endothelial cells and stem cells. In some organisms, CD71 is an enhancer of bone resorption, plays a role in the upregulation of B cell proliferation and is an enhancer of T cell proliferation. From a research standpoint, it is of biological interest due to its association with essential macromolecules/ligands such as Transferrin. CD71 is a fairly uncommon antibody target, with a little more than 4000 publications in the last decade. Even still, CD71 is essential for immunology research, commonly serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to iFluor® 546 (ex/em = 541/557 nm). It is compatible with the 532 nm laser and 575/25 nm bandpass filter (for example, as in the BD FACSymphony™ A5).
product image
product image
CatalogSize
Price
Quantity
10711080100 tests
Price
10711081500 tests
Price
 
Antibody properties

Other namesT9, Transferrin receptor, TFRC
CloneHI166
HostMouse
IsotypeIgG1
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Correction factor (260 nm)0.25
Correction factor (280 nm)0.15
Extinction coefficient (cm -1 M -1)
100000
1
Excitation (nm)541
Emission (nm)557
Quantum yield
0.67
1
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on March 31, 2026